SEARCH

SEARCH BY CITATION

References

  • 1
    Coiffier B,Lepage E,Briere J,Herbrecht R,Tilly H,Bouabdallah R,Morel P,Van Den Neste E,Salles G,Gaulard P,Reyes F,Lederlin P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 23542.
  • 2
    Pfreundschuh M,Trumper L,Osterborg A,Pettengell R,Trneny M,Imrie K,Ma D,Gill D,Walewski J,Zinzani PL,Stahel R,Kvaloy S, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 37991.
  • 3
    Slamon DJ,Leyland-Jones B,Shak S,Fuchs H,Paton V,Bajamonde A,Fleming T,Eiermann W,Wolter J,Pegram M,Baselga J,Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 78392.
  • 4
    Hurwitz H,Fehrenbacher L,Novotny W,Cartwright T,Hainsworth J,Heim W,Berlin J,Baron A,Griffing S,Holmgren E,Ferrara N,Fyfe G, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 233542.
  • 5
    Sandler A,Gray R,Perry MC,Brahmer J,Schiller JH,Dowlati A,Lilenbaum R,Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 254250.
  • 6
    Bonner JA,Harari PM,Giralt J,Azarnia N,Shin DM,Cohen RB,Jones CU,Sur R,Raben D,Jassem J,Ove R,Kies MS, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 56778.
  • 7
    Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 735968.
  • 8
    Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1: 11829.
  • 9
    Glennie MJ,van de Winkel JG. Renaissance of cancer therapeutic antibodies. Drug Discov Today 2003; 8: 50310.
  • 10
    Voso MT,Pantel G,Rutella S,Weis M,D'Alo F,Urbano R,Leone G,Haas R,Hohaus S. Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica 2002; 87: 91825.
  • 11
    Clynes RA,Towers TL,Presta LG,Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 4436.
  • 12
    Cartron G,Dacheux L,Salles G,Solal-Celigny P,Bardos P,Colombat P,Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 7548.
  • 13
    Niwa R,Hatanaka S,Shoji-Hosaka E,Sakurada M,Kobayashi Y,Uehara A,Yokoi H,Nakamura K,Shitara K. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism. Clin Cancer Res 2004; 10: 624855.
  • 14
    Fischer L,Penack O,Gentilini C,Nogai A,Muessig A,Thiel E,Uharek L. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp Hematol 2006; 34: 7539.
  • 15
    Bhat R,Watzl C. Serial killing of tumor cells by human natural killer cells—enhancement by therapeutic antibodies. PLoS ONE 2007; 2: e326.
  • 16
    Ito A,Ishida T,Yano H,Inagaki A,Suzuki S,Sato F,Takino H,Mori F,Ri M,Kusumoto S,Komatsu H,Iida S, et al. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rγnull mouse model. Cancer Immunol Immunother 2008 Dec 2. [Epub ahead of print].
  • 17
    Ishida T,Iida S,Akatsuka Y,Ishii T,Miyazaki M,Komatsu H,Inagaki H,Okada N,Fujita T,Shitara K,Akinaga S,Takahashi T, et al. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma. Clin Cancer Res 2004; 10: 752939.
  • 18
    Ishida T,Utsunomiya A,Iida S,Inagaki H,Takatsuka Y,Kusumoto S,Takeuchi G,Shimizu S,Ito M,Komatsu H,Wakita A,Eimoto T, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003; 9: 362534.
  • 19
    Sconocchia G,Lau M,Provenzano M,Rezvani K,Wongsena W,Fujiwara H,Hensel N,Melenhorst J,Li J,Ferrone S,Barrett AJ. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. Blood 2005; 106: 366672.
  • 20
    Niwa R,Sakurada M,Kobayashi Y,Uehara A,Matsushima K,Ueda R,Nakamura K,Shitara K. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 2005; 11: 232736.
  • 21
    North J,Bakhsh I,Marden C,Pittman H,Addison E,Navarrete C,Anderson R,Lowdell MW. Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation. J Immunol 2007; 178: 8594.
  • 22
    Yano H,Ishida T,Inagaki A,Ishii T,Ding J,Kusumoto S,Komatsu H,Iida S,Inagaki H,Ueda R. Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome. Clin Cancer Res 2007; 13: 6494500.
  • 23
    Golay J,Zaffaroni L,Vaccari T,Lazzari M,Borleri GM,Bernasconi S,Tedesco F,Rambaldi A,Introna M. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 39008.
  • 24
    Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23: 22574.
  • 25
    Binyamin L,Alpaugh RK,Hughes TL,Lutz CT,Campbell KS,Weiner LM. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol 2008; 180: 6392401.
  • 26
    Moretta A,Bottino C,Vitale M,Pende D,Cantoni C,Mingari MC,Biassoni R,Moretta L. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001; 19: 197223.
  • 27
    Brown MH,Boles K,van der Merwe PA,Kumar V,Mathew PA,Barclay AN. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J Exp Med 1998; 188: 208390.
  • 28
    Nowbakht P,Ionescu MC,Rohner A,Kalberer CP,Rossy E,Mori L,Cosman D,De Libero G,Wodnar-Filipowicz A. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 2005; 105: 361522.
  • 29
    Cosman D,Mullberg J,Sutherland CL,Chin W,Armitage R,Fanslow W,Kubin M,Chalupny NJ. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001; 14: 12333.
  • 30
    Sutherland CL,Rabinovich B,Chalupny NJ,Brawand P,Miller R,Cosman D. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. Blood 2006; 108: 131319.
  • 31
    Waldhauer I,Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008; 27: 593243.
  • 32
    Nausch N,Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008: 27; 594458.
  • 33
    Carosella ED,Dausset J. Progress of HLA-G in cancer. Semin Cancer Biol 2003; 13: 31516.
  • 34
    Seliger B,Abken H,Ferrone S. HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol 2003; 24: 827.
  • 35
    Liu CC,Walsh CM,Young JD. Perforin: structure and function. Immunol Today 1995; 16: 194201.
  • 36
    Trapani JA,Sutton VR,Smyth MJ. CTL granules: evolution of vesicles essential for combating virus infections. Immunol Today 1999; 20: 3516.
  • 37
    Mai J,Finley RL,Jr,Waisman DM,Sloane BF. Human procathepsin B interacts with the annexin II tetramer on the surface of tumor cells. J Biol Chem 2000; 275: 1280612.
  • 38
    Hulkower KI,Butler CC,Linebaugh BE,Klaus JL,Keppler D,Giranda VL,Sloane BF. Fluorescent microplate assay for cancer cell-associated cathepsin B. Eur J Biochem 2000; 267: 416570.
  • 39
    Balaji KN,Schaschke N,Machleidt W,Catalfamo M,Henkart PA. Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation. J Exp Med 2002; 196: 493503.
  • 40
    Bryceson YT,March ME,Ljunggren HG,Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006; 107: 15966.
  • 41
    Niwa R,Shoji-Hosaka E,Sakurada M,Shinkawa T,Uchida K,Nakamura K,Matsushima K,Ueda R,Hanai N,Shitara K. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 2004; 64: 212733.
  • 42
    Ishida T,Ishii T,Inagaki A,Yano H,Kusumoto S,Ri M,Komatsu H,Iida S,Inagaki H,Ueda R. The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma. Leukemia 2006; 20: 21628.
  • 43
    Ishida T,Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 2006; 97: 113946.
  • 44
    Yano H,Ishida T,Imada K,Sakai T,Ishii T,Inagaki A,Iida S,Uchiyama T,Ueda R. Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSF. Br J Haematol 2008; 140: 5869.
  • 45
    Poggi A,Venturino C,Catellani S,Clavio M,Miglino M,Gobbi M,Steinle A,Ghia P,Stella S,Caligaris-Cappio F,Zocchi MR. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res 2004; 64: 91729.
  • 46
    Armeanu S,Bitzer M,Lauer UM,Venturelli S,Pathil A,Krusch M,Kaiser S,Jobst J,Smirnow I,Wagner A,Steinle A,Salih HR. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005; 65: 63219.
  • 47
    von Strandmann EP,Hansen HP,Reiners KS,Schnell R,Borchmann P,Merkert S,Simhadri VR,Draube A,Reiser M,Purr I,Hallek M,Engert A. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 2006; 107: 195562.